These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 24334179)

  • 1. Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): a randomized, double-blind, placebo-controlled, two-stage study.
    Macarthur RD; Hawkins TN; Brown SJ; Lamarca A; Clay PG; Barrett AC; Bortey E; Paterson C; Golden PL; Forbes WP
    HIV Clin Trials; 2013; 14(6):261-73. PubMed ID: 24334179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crofelemer, a novel agent for treatment of secretory diarrhea.
    Crutchley RD; Miller J; Garey KW
    Ann Pharmacother; 2010 May; 44(5):878-84. PubMed ID: 20388859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crofelemer, a novel agent for treatment of non-infectious diarrhea in HIV-infected persons.
    Chordia P; MacArthur RD
    Expert Rev Gastroenterol Hepatol; 2013 Sep; 7(7):591-600. PubMed ID: 24070150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients.
    Mangel AW; Chaturvedi P
    Digestion; 2008; 78(4):180-6. PubMed ID: 19092244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crofelemer: a review of its use in the management of non-infectious diarrhoea in adult patients with HIV/AIDS on antiretroviral therapy.
    Frampton JE
    Drugs; 2013 Jul; 73(10):1121-9. PubMed ID: 23807722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Clinical Trial: Crofelemer Treatment in Women With Diarrhea-Predominant Irritable Bowel Syndrome.
    Nee J; Salley K; Ludwig AG; Sommers T; Ballou S; Takazawa E; Duehren S; Singh P; Iturrino J; Katon J; Lee HN; Rangan V; Lembo AJ
    Clin Transl Gastroenterol; 2019 Dec; 10(12):e00110. PubMed ID: 31800542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crofelemer, a novel antisecretory agent approved for the treatment of HIV-associated diarrhea.
    Yeo QM; Crutchley R; Cottreau J; Tucker A; Garey KW
    Drugs Today (Barc); 2013 Apr; 49(4):239-52. PubMed ID: 23616951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of orally administered crofelemer on the incidence and severity of neratinib-induced diarrhea in female dogs.
    Guy M; Teixeira A; Shrier A; Meschter C; Bolognese J; Chaturvedi P
    PLoS One; 2024; 19(1):e0282769. PubMed ID: 38265977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crofelemer for the treatment of secretory diarrhea.
    Cottreau J; Tucker A; Crutchley R; Garey KW
    Expert Rev Gastroenterol Hepatol; 2012 Feb; 6(1):17-23. PubMed ID: 22149578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crofelemer: In HIV Associated Diarrhea and Secretory Diarrhea - A Patent Perspective.
    Biswal S
    Recent Pat Antiinfect Drug Discov; 2014; 9(2):136-43. PubMed ID: 25851117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
    Chang L; Ameen VZ; Dukes GE; McSorley DJ; Carter EG; Mayer EA
    Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crofelemer for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy.
    Castro JG; Chin-Beckford N
    Expert Rev Clin Pharmacol; 2015; 8(6):683-90. PubMed ID: 26517110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of probiotic Lactobacillus rhamnosus GG on prolonged, noninfectious diarrhea in HIV Patients on antiretroviral therapy: a randomized, placebo-controlled, crossover study.
    Salminen MK; Tynkkynen S; Rautelin H; Poussa T; Saxelin M; Ristola M; Valtonen V; Järvinen A
    HIV Clin Trials; 2004; 5(4):183-91. PubMed ID: 15472792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study.
    Tack JF; Miner PB; Fischer L; Harris MS
    Aliment Pharmacol Ther; 2011 Oct; 34(8):868-77. PubMed ID: 21883322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
    Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
    Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Albendazole chemotherapy for treatment of diarrhoea in patients with AIDS in Zambia: a randomised double blind controlled trial.
    Kelly P; Lungu F; Keane E; Baggaley R; Kazembe F; Pobee J; Farthing M
    BMJ; 1996 May; 312(7040):1187-91. PubMed ID: 8634560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDS.
    Patel TS; Crutchley RD; Tucker AM; Cottreau J; Garey KW
    HIV AIDS (Auckl); 2013; 5():153-62. PubMed ID: 23888120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of crofelemer extract on severity and consistency of experimentally induced enterotoxigenic Escherichia coli diarrhea in newborn Holstein calves.
    Teixeira AG; Stephens L; Divers TJ; Stokol T; Bicalho RC
    J Dairy Sci; 2015 Nov; 98(11):8035-43. PubMed ID: 26298758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
    Krause R; Ameen V; Gordon SH; West M; Heath AT; Perschy T; Carter EG
    Am J Gastroenterol; 2007 Aug; 102(8):1709-19. PubMed ID: 17509028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
    Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.